Ruo W. Steensma

Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-<i>N</i>2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-<i>N</i>4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials

Thomas H. Marsilje, Wei Pei, Bei Chen et al. · Journal of Medicinal Chemistry · 2013 · 405 citations · Full text

Chemoprevention Strategy, Pharmacotherapy, Structure–activity Relationships +21

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK

Anna Galkin, Jonathan S. Melnick, Sung Joon Kim et al. · Proceedings of the National Academy of Sciences · 2006 · 375 citations · Full text

Drug Target, Immunology, Cell Death +22

Piperazine-Based CCR5 Antagonists as HIV-1 Inhibitors. IV. Discovery of 1-[(4,6-Dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-{2-methoxy-1(<i>R</i>)-4-(trifluoromethyl)phenyl}ethyl-3(<i>S</i>)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a Potent, Highly Selective, and Orally Bioavailable CCR5 Antagonist

Jayaram R. Tagat, Stuart W. McCombie, Dennis V. Nazareno et al. · Journal of Medicinal Chemistry · 2004 · 136 citations · Full text

Excellent Receptor Selectivity, Immunology, Hiv-1 Inhibitors +19

Piperazine-Based CCR5 Antagonists as HIV-1 Inhibitors. II. Discovery of 1-[(2,4-Dimethyl-3-pyridinyl)carbonyl]-4- methyl-4-[3(<i>S</i>)-methyl-4-[1(<i>S</i>)-[4-(trifluoro- methyl)phenyl]ethyl]-1-piperazinyl]- piperidine <i>N</i>1-Oxide (Sch-350634), an Orally Bioavailable, Potent CCR5 Antagonist

Jayaram R. Tagat, Ruo W. Steensma, Stuart W. McCombie et al. · Journal of Medicinal Chemistry · 2001 · 112 citations · Full text

Compound 8, Immunology, Hiv-1 Inhibitors +20

Inhibition of the development of collagen‐induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5

Michel Vierboom, Paul J. Zavodny, Chuan‐Chu Chou et al. · Arthritis & Rheumatism · 2005 · 92 citations